Literature DB >> 17031177

Intestinal fibrosis in human and experimental inflammatory bowel disease.

P K Lund1, C C Zuniga.   

Abstract

Fibrosis is a serious complication of Crohn disease for which there is no effective therapy. It is unclear why fibrosis, particularly fibrosis of the mucosal layer, develops in Crohn disease and not in ulcerative colitis. Smooth muscle cells, subepithelial myofibroblasts, and fibroblasts have traditionally been considered mediators of fibrosis, but new information points to a role of interstitial cells of Cajal and mast cells. Recent evidence about the role of each of these cell types in fibrosis in Crohn disease or other inflammatory bowel diseases is described. Hypothetical models to describe how altered function of these cells could underlie fibrosis of the mucosa or submucosal layers are presented. Fibrosis is not well characterized in any animal model of inflammatory bowel disease. The merits of several animal models for defining the mechanisms of inflammation-induced intestinal fibrosis are reviewed.

Entities:  

Year:  2001        PMID: 17031177     DOI: 10.1097/00001574-200107000-00004

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  14 in total

Review 1.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease.

Authors:  Florian Rieder; Sean Kessler; Miquel Sans; Claudio Fiocchi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-09       Impact factor: 4.052

2.  Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis.

Authors:  Florian Rieder; Sean P Kessler; Gail A West; Shardul Bhilocha; Carol de la Motte; Tammy M Sadler; Banu Gopalan; Eleni Stylianou; Claudio Fiocchi
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

3.  Themes in fibrosis and gastrointestinal inflammation.

Authors:  Claudio Fiocchi; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

Review 4.  Animal models for studying epithelial barriers in neonatal necrotizing enterocolitis, inflammatory bowel disease and colorectal cancer.

Authors:  Tiaosi Xing; Rolando Camacho Salazar; Yan-Hua Chen
Journal:  Tissue Barriers       Date:  2017-08-10

Review 5.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

6.  GPR65 (TDAG8) inhibits intestinal inflammation and colitis-associated colorectal cancer development in experimental mouse models.

Authors:  Mona A Marie; Edward J Sanderlin; Swati Satturwar; Heng Hong; Kvin Lertpiriyapong; Deepak Donthi; Li V Yang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-10-08       Impact factor: 5.187

7.  Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.

Authors:  Jill M Hoffman; Stavroula Baritaki; Jonathan J Ruiz; Aristea Sideri; Charalabos Pothoulakis
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

8.  Indirubin, a Constituent of the Chinese Herbal Medicine Qing-Dai, Attenuates Dextran Sulfate Sodium-induced Murine Colitis.

Authors:  Naruo Tokuyasu; Kohei Shomori; Kuniki Amano; Soichiro Honjo; Teruhisa Sakamoto; Joji Watanabe; Masataka Amisaki; Masaki Morimoto; Ei Uchinaka; Takuki Yagyu; Hiroaki Saito; Hisao Ito; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2018-06-18       Impact factor: 1.641

9.  Mouse Models of Intestinal Fibrosis.

Authors:  Jiannan Li; Dina Dejanovic; Megan T Zangara; Jyotsna Chandra; Christine McDonald; Florian Rieder
Journal:  Methods Mol Biol       Date:  2021

10.  miR-200b is involved in intestinal fibrosis of Crohn's disease.

Authors:  Yingwei Chen; Wensong Ge; Leiming Xu; Chunying Qu; Mingjie Zhu; Wenzhu Zhang; Yongtao Xiao
Journal:  Int J Mol Med       Date:  2012-01-23       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.